Acute Myeloid Leukemia, Not Otherwise Specified

Acute Myeloid Leukemia, Not Otherwise Specified — Trials · CancerIndex

Clinical trials

Registered studies

100 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 11
Recruiting: 6
Ph III recruiting: 0
Growth YoY: —
Industry share: 9%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (25)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06504459	Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML	recruiting	Phase 2	40	OHSU Knight Cancer InstituteOTHER	1	Sep 16, 2026	clinicaltrials
NCT00392353	Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia	active not recruiting	Phase 1 / Phase 2	135	National Cancer Institute (NCI)NIH	1	Aug 7, 2026